Literature DB >> 25809272

Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.

B I Freedman1,2, B A Julian3, S O Pastan4, A K Israni5,6, D Schladt6, M D Gautreaux7, V Hauptfeld8, R A Bray9, H M Gebel9, A D Kirk10, R S Gaston3, J Rogers11, A C Farney11, G Orlando11, R J Stratta11, S Mohan12, L Ma1, C D Langefeld13, P J Hicks2, N D Palmer2, P L Adams1, A Palanisamy1, A M Reeves-Daniel1, J Divers13.   

Abstract

Apolipoprotein L1 gene (APOL1) nephropathy variants in African American deceased kidney donors were associated with shorter renal allograft survival in a prior single-center report. APOL1 G1 and G2 variants were genotyped in newly accrued DNA samples from African American deceased donors of kidneys recovered and/or transplanted in Alabama and North Carolina. APOL1 genotypes and allograft outcomes in subsequent transplants from 55 U.S. centers were linked, adjusting for age, sex and race/ethnicity of recipients, HLA match, cold ischemia time, panel reactive antibody levels, and donor type. For 221 transplantations from kidneys recovered in Alabama, there was a statistical trend toward shorter allograft survival in recipients of two-APOL1-nephropathy-variant kidneys (hazard ratio [HR] 2.71; p = 0.06). For all 675 kidneys transplanted from donors at both centers, APOL1 genotype (HR 2.26; p = 0.001) and African American recipient race/ethnicity (HR 1.60; p = 0.03) were associated with allograft failure. Kidneys from African American deceased donors with two APOL1 nephropathy variants reproducibly associate with higher risk for allograft failure after transplantation. These findings warrant consideration of rapidly genotyping deceased African American kidney donors for APOL1 risk variants at organ recovery and incorporation of results into allocation and informed-consent processes. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research / practice; donors and donation: deceased; genetics; genomics; kidney disease; kidney transplantation / nephrology; molecular biology; translational research / science

Mesh:

Substances:

Year:  2015        PMID: 25809272      PMCID: PMC4784684          DOI: 10.1111/ajt.13223

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  36 in total

1.  Living donor nephrectomy: understanding long-term risk in minority populations.

Authors:  R S Gaston; C J Young
Journal:  Am J Transplant       Date:  2010-12       Impact factor: 8.086

2.  African American living-kidney donors should be screened for APOL1 risk alleles.

Authors:  David M Cohen; Anuja Mittalhenkle; David L Scott; Carlton J Young; Douglas J Norman
Journal:  Transplantation       Date:  2011-10-15       Impact factor: 4.939

3.  APOL1 variants and kidney disease in people of recent African ancestry.

Authors:  Giulio Genovese; David J Friedman; Martin R Pollak
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

4.  The APOL1 gene and allograft survival after kidney transplantation.

Authors:  A M Reeves-Daniel; J A DePalma; A J Bleyer; M V Rocco; M Murea; P L Adams; C D Langefeld; D W Bowden; P J Hicks; R J Stratta; J-J Lin; D F Kiger; M D Gautreaux; J Divers; B I Freedman
Journal:  Am J Transplant       Date:  2011-04-12       Impact factor: 8.086

Review 5.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.

Authors:  Barry I Freedman; Jeffrey B Kopp; Carl D Langefeld; Giulio Genovese; David J Friedman; George W Nelson; Cheryl A Winkler; Donald W Bowden; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 10.121

6.  Racial variation in medical outcomes among living kidney donors.

Authors:  Krista L Lentine; Mark A Schnitzler; Huiling Xiao; Georges Saab; Paolo R Salvalaggio; David Axelrod; Connie L Davis; Kevin C Abbott; Daniel C Brennan
Journal:  N Engl J Med       Date:  2010-08-19       Impact factor: 91.245

Review 7.  The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill.

Authors:  Benoit Vanhollebeke; Etienne Pays
Journal:  Mol Microbiol       Date:  2010-04-01       Impact factor: 3.501

8.  Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs.

Authors:  Harini A Chakkera; Ann M O'Hare; Kirsten L Johansen; Denise Hynes; Kevin Stroupe; Philip M Colin; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2004-11-24       Impact factor: 10.121

9.  Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry.

Authors:  S Takemoto; P I Terasaki; J M Cecka; Y W Cho; D W Gjertson
Journal:  N Engl J Med       Date:  1992-09-17       Impact factor: 91.245

10.  Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene.

Authors:  Shay Tzur; Saharon Rosset; Revital Shemer; Guennady Yudkovsky; Sara Selig; Ayele Tarekegn; Endashaw Bekele; Neil Bradman; Walter G Wasser; Doron M Behar; Karl Skorecki
Journal:  Hum Genet       Date:  2010-07-16       Impact factor: 4.132

View more
  85 in total

1.  How complicated can it be? The link between APOL1 risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseases.

Authors:  Chien-An A Hu; Patricio E Ray
Journal:  Nephrol Dial Transplant       Date:  2015-10-03       Impact factor: 5.992

Review 2.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

Review 3.  Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.

Authors:  Kimberly J Reidy; Rebecca Hjorten; Rulan S Parekh
Journal:  Curr Opin Pediatr       Date:  2018-04       Impact factor: 2.856

4.  Transplantation: APOL1 gene variants associated with renal allograft failure.

Authors:  Rebecca Kelsey
Journal:  Nat Rev Urol       Date:  2015-04-14       Impact factor: 14.432

5.  You Are Just Now Telling Us About This? African American Perspectives of Testing for Genetic Susceptibility to Kidney Disease.

Authors:  Ebele M Umeukeje; Bessie A Young; Stephanie M Fullerton; Kerri Cavanaugh; Delia Owens; James G Wilson; Wylie Burke; Erika Blacksher
Journal:  J Am Soc Nephrol       Date:  2019-03-11       Impact factor: 10.121

Review 6.  Evaluating the promise of inclusion of African ancestry populations in genomics.

Authors:  Amy R Bentley; Shawneequa L Callier; Charles N Rotimi
Journal:  NPJ Genom Med       Date:  2020-02-25       Impact factor: 8.617

7.  Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion.

Authors:  Daniel Granado; Daria Müller; Vanessa Krausel; Etty Kruzel-Davila; Christian Schuberth; Melanie Eschborn; Roland Wedlich-Söldner; Karl Skorecki; Hermann Pavenstädt; Ulf Michgehl; Thomas Weide
Journal:  J Am Soc Nephrol       Date:  2017-07-10       Impact factor: 10.121

8.  Identifying the Intracellular Function of APOL1.

Authors:  Leslie A Bruggeman; John F O'Toole; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-02-14       Impact factor: 10.121

Review 9.  Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.

Authors:  Madhav C Menon; Barbara Murphy; Peter S Heeger
Journal:  J Am Soc Nephrol       Date:  2017-01-06       Impact factor: 10.121

10.  APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8.

Authors:  Sethu M Madhavan; John F O'Toole; Martha Konieczkowski; Laura Barisoni; David B Thomas; Santhi Ganesan; Leslie A Bruggeman; Matthias Buck; John R Sedor
Journal:  JCI Insight       Date:  2017-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.